Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

398.00p
   
  • Change Today:
    -10.50p
  • 52 Week High: 445.00p
  • 52 Week Low: 166.80p
  • Currency: UK Pounds
  • Shares Issued: 105.36m
  • Volume: 91,279
  • Market Cap: £419.33m
  • RiskGrade: 125

Oxford Biomedica inks LSA with new US biotech partner

By Iain Gilbert

Date: Wednesday 07 Sep 2022

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck a new licence and supply agreement with an unnamed US partner.
Oxford Biomedica said on Wednesday that the new licence and supply agreement will grant its new partner a non-exclusive licence to utilise its LentiVector platform for use in the application of its lead programme - a cell-based therapy targeting a rare indication.

The London-listed group noted that under the terms of the five-year clinical supply arrangement, it will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials.

Oxford Biomedica will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of any drug product sold that utilises its LentiVector platform.

Chair and interim chief executive Dr Roch Doliveux said: "This partnership further demonstrates Oxford Biomedica's world leadership in the delivery of viral vectors for cell and gene therapies and the momentum we are building, with this being the fifth new or expanded customer partnership we have announced this year."





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price 398.00p
Change Today -10.50p
% Change -2.57 %
52 Week High 445.00p
52 Week Low 166.80p
Volume 91,279
Shares Issued 105.36m
Market Cap £419.33m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.96% below the market average31.96% below the market average31.96% below the market average31.96% below the market average31.96% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Price Trend
88.50% above the market average88.50% above the market average88.50% above the market average88.50% above the market average88.50% above the market average
96.00% above the sector average96.00% above the sector average96.00% above the sector average96.00% above the sector average96.00% above the sector average
Income Not Available
Growth
52.8% below the market average52.8% below the market average52.8% below the market average52.8% below the market average52.8% below the market average
52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 5
Sell 0
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 31-Oct-2024

Time Volume / Share Price
16:40 15,468 @ 397.43p
16:35 18,278 @ 398.00p
16:35 7 @ 398.00p
16:35 357 @ 398.00p
16:35 242 @ 398.00p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page